Literature DB >> 19452406

Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia.

Massimo Franchini1, Martina Montagnana, Giovanni Targher, Dino Veneri, Marco Zaffanello, Gian Luca Salvagno, Franco Manzato, Giuseppe Lippi.   

Abstract

It is well known that the clinical phenotype of hemophilia may vary greatly among patients with the same apparent level of coagulation factor and the same genetic mutation. Thus, patients with severe hemophilia may experience a severe phenotype or only a milder bleeding tendency, suggesting some other moderating influence. To elucidate the mechanism of this heterogeneity, some investigators have recently suggested that inherited thrombophilic factors may play a role in the milder clinical presentation of severe hemophilia. In this review, we summarize current knowledge with respect to the modulation of the clinical phenotype of severe hemophilia by prothrombotic genetic risk factors. Although the published literature seems to indicate a protective effect for the coinheritance of factor V Leiden, the limited data available do not permit any firm conclusions. Further trials on a large population of patients are needed to establish the role of genetic thrombophilia in the phenotypic expression of severe hemophilia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19452406     DOI: 10.1055/s-0029-1222609

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

Review 2.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

Review 3.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

Review 4.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 5.  An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B.

Authors:  Nicoletta Machin; Margaret V Ragni
Journal:  J Blood Med       Date:  2018-08-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.